Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Cash from Operations (2016 - 2019)

Historic Cash from Operations for Soleno Therapeutics (SLNO) over the last 7 years, with Q4 2019 value amounting to -$5.1 million.

  • Soleno Therapeutics' Cash from Operations fell 3586.72% to -$5.1 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$17.4 million, marking a year-over-year decrease of 4872.04%. This contributed to the annual value of -$69.1 million for FY2024, which is 17706.5% down from last year.
  • According to the latest figures from Q4 2019, Soleno Therapeutics' Cash from Operations is -$5.1 million, which was down 3586.72% from -$4.7 million recorded in Q3 2019.
  • Soleno Therapeutics' Cash from Operations' 5-year high stood at -$1.8 million during Q1 2015, with a 5-year trough of -$5.1 million in Q4 2019.
  • Its 5-year average for Cash from Operations is -$3.1 million, with a median of -$2.8 million in 2015.
  • In the last 5 years, Soleno Therapeutics' Cash from Operations tumbled by 25540.28% in 2015 and then surged by 4520.58% in 2017.
  • Soleno Therapeutics' Cash from Operations (Quarter) stood at -$3.4 million in 2015, then grew by 20.41% to -$2.7 million in 2016, then decreased by 1.6% to -$2.7 million in 2017, then plummeted by 36.75% to -$3.7 million in 2018, then crashed by 35.87% to -$5.1 million in 2019.
  • Its Cash from Operations stands at -$5.1 million for Q4 2019, versus -$4.7 million for Q3 2019 and -$3.9 million for Q2 2019.